News

Fannie Mae Achieves $4 Billion Net Income in Latest Quarter

Fannie Mae Achieves $4 Billion Net Income in Latest Quarter

Fannie Mae Delivers Impressive Financial Performance

Fannie Mae has reported a remarkable net income of $4.0 billion for the latest quarter, indicating its strong position in the financial landscape. This impressive figure reflects the company's efficiency and the positive trends in the housing market, coupled with its dedication to enhancing access to homeownership and rental opportunities for many individuals and families.

Third Quarter Financial Highlights

The financial results for the third quarter are documented in Fannie Mae's Third Quarter 2024 Form 10-Q, submitted to the Securities and Exchange Commission. This detailed filing allows stakeholders to gain insights into the company’s financial health and operations for the period ending September 30, 2024. Key highlights include its sustained profitability and the strategic measures implemented to navigate the evolving economic environment.

Net Income Insights

The reported net income of $4 billion not only showcases Fannie Mae’s robustness but also emphasizes its proactive approach to market fluctuations. The financial results demonstrate how effective management decisions contribute to maintaining a solid foundation amid various external challenges.

Financial Support and Market Influence

Fannie Mae plays a crucial role in supporting equitable housing markets. By providing access to fixed-rate mortgages, the company helps millions achieve their dreams of homeownership. Its operations also significantly influence the rental market, demonstrating its commitment to affordable housing solutions across the nation.

Upcoming Conference Call

To discuss these promising results, Fannie Mae has scheduled a conference call today at 8:00 a.m., ET. This session will be accessible in listen-only mode, allowing participants to gain further insights into the company's operations and future plans.

How to Join the Call

For those interested in participating, the conference call will be available through a webcast link. Attendees can conveniently access the presentation from their devices and listen to the detailed analysis provided by the company’s leadership team.

Fannie Mae’s Commitment to Innovation

Fannie Mae continues to drive responsible innovation, facilitating a seamless home-buying experience for customers. The company’s continuous efforts to improve processes demonstrate its commitment to both current and future homeowners, making the journey towards homeownership smoother and more achievable.

About Fannie Mae

Fannie Mae is dedicated to fostering equitable access to quality housing. By offering financial products and services tailored to individuals' needs, the company empowers millions by making homeownership attainable. Fannie Mae operates with the vision of transforming the housing sector, ensuring everyone has the opportunity to secure a place to call home.

Frequently Asked Questions

What is the net income reported by Fannie Mae for the latest quarter?

Fannie Mae reported a net income of $4.0 billion for the third quarter of 2024.

When was the Third Quarter 2024 Form 10-Q filed?

The Third Quarter 2024 Form 10-Q was filed with the Securities and Exchange Commission recently and details the company's financial results.

How does Fannie Mae support affordable housing?

Fannie Mae supports affordable housing by providing access to fixed-rate mortgages and facilitating responsible lending practices.

When is the conference call to discuss the results?

The conference call is scheduled for today at 8:00 a.m., ET, and will be open for participants to listen in.

What role does Fannie Mae play in the market?

Fannie Mae plays a crucial role in the housing market by supporting homeownership and influencing rental opportunities, thereby contributing to the overall stability of the housing industry.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 76

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 35

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

Updated Category News Views 0

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 46

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 7

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
Florida Cancer Center Expands Expertise with New Oncologist

Updated Category News Views 0

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Continue Reading
Kansai Medical Ushers in New Era of Cancer Research

Updated Category News Views 3

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Continue Reading
GELITA Showcases Collagen Innovations at SupplySide 2026

Updated Category News Views 10

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

Continue Reading
Chicago Scenic Studios’ Equipment Up for Grabs in Auction

Updated Category News Views 9

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 46

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

First Trust Mortgage Income Fund Announces Monthly Dividend

Updated Category News Views 43

First Trust Mortgage Income Fund's Monthly Distribution Announcement First Trust Mortgage Income Fund (NYSE: FMY) has declared its upcoming monthly common share distribution, marking an important date for its shareholders. The distribution set at $0.075 per share is payable soon, showing the Fund's commitment to providing consistent returns. Details About the Distribution...

Continue Reading
Akeso's 2024 Annual Report: Innovations in Bispecific Therapies

Updated Category News Views 718

Revolutionizing Cancer Treatment Through Innovation Akeso Inc. has announced its annual results for 2024, showcasing major achievements in biotechnology innovation. The company has focused on developing cutting-edge therapies, particularly in bispecific antibodies, aimed at transforming the treatment landscape for various cancers. Key Accolades and Advancements Key...

Continue Reading
Rona Therapeutics Receives Approval for RN1871 siRNA Treatment

Updated Category News Views 395

Rona Therapeutics Makes Significant Strides in Hypertension Treatment Rona Therapeutics, a biotechnology leader in RNA-targeted therapies, has achieved an impressive milestone with the approval of its Investigational New Drug (IND) application for RN1871 by China's National Medical Products Administration (NMPA). This innovative small interfering RNA (siRNA) drug is...

Continue Reading
Fleet Management Market Growth Forecast of USD 52.23 Billion

Updated Category News Views 150

Understanding Fleet Management Market Evolution The global fleet management market is poised for significant growth, expected to expand by USD 52.23 billion between 2025 and 2029. This growth is primarily fueled by the surge in e-commerce and the pressing need for last-mile delivery solutions. As industries continue to evolve, the integration of technology is transforming...

Continue Reading
Projected Growth and Challenges in the Anisole Market by 2033

Updated Category News Views 105

Understanding the Global Anisole Market Trends The global anisole market has been on a robust growth trajectory. Valued at approximately US$ 98.78 million as of recent estimates, it is poised to reach a remarkable US$ 165.48 million by 2033, with a compound annual growth rate (CAGR) of 5.9% from 2025 onwards. This upward trend indicates a significant demand for anisole...

Continue Reading